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Introduction. In the animal model, preconditioning is a powerful weapon against ischemic damage. The reason why the human
heart cannot be protected from ischemic damage by preconditioning remains unclear. There are assumptions that the lack of
preconditioning in humans is caused by concomitant diseases such as dyslipoproteinemia and arteriosclerosis. This study
investigates whether dyslipoproteinemia and the resulting arteriosclerosis can be a cause of a reduced precondition effect of
heart in mice. Methods. LDL receptor-deficient mice were fed a long-term (14-16 weeks) high-fat atherogenic diet to induce
arteriosclerosis. Arteriosclerosis was identified by histological examination and vessel contraction tests. LDLR-/- and wild-type
mice were randomly assigned to anesthetic-induced, remote ischemic, or no preconditioning. All mice were subjected to 45
minutes of coronary artery occlusion and 180 minutes of reperfusion. The area at risk and infarct size were determined by
Evans Blue and triphenyltetrazolium chloride staining. Results. Histopathological examination showed atherosclerosis in high-fat
atherogenic fed LDLR-/- mice, and the vessel relaxation capacity was significantly reduced compared to wild-type mice. In the
wild type, as expected, infarct size was significantly reduced by preconditioning compared to the control. In LDLR-/- mice,
infarct size was significantly reduced by preconditioning compared to the control. Surprisingly, the LDLR-/- control group also
had a significantly reduced infarct size compared to the wild-type control group. Conclusion. We were able to demonstrate that
a high-fat diet morphologically and functionally triggered atherosclerosis in LDLR-/- mice. Interestingly, LDLR-/- mice with an
atherogenic diet had smaller infarct sizes compared to wild-type mice. Moreover, preconditioning additionally reduced
myocardial infarct size in LDLR-/- mice. A long-term high-fat atherogenic diet and preconditioning seem to result in additive
cardioprotection in LDLR-/- mice.
1. Introduction
Acute myocardial infarction (AMI) is one of the leading
causes of mortality and morbidity worldwide. There has been
an extensive search for cardioprotective therapies to reduce
myocardial ischemia-reperfusion (IR) injury. Ischemic pre-
conditioning is the intriguing phenomenon whereby brief
and transient episodes of ischemia that, as such, do not cause
tissue necrosis instead render tissue and organs resistant to a
sustained ischemic insult. Since the first report by Murry
et al. of preconditioning to prevent ischemia reperfusion
injury (IRI), numerous studies have been conducted [1]. In
the following years, many in vitro and in vivo studies have
provided strong evidence for the infarct-sparing potential of
preconditioning, be it ischemic (IPC), remote ischemic
(RIPC), or anesthetic-induced (APC) preconditioning. The
overall effect of preconditioning in animal studies has raised
hopes for finding an infarct-sparing intervention in the clin-
ical setting. However, data from large randomized prospec-
tive studies have been disappointing [2].
IPC with repeat episodes of brief ischemia within one
vascular bed protects the organ (e.g., myocardium) from a
subsequent prolonged episode of ischemia in that same vas-
cular bed [3]. First described by Murray, this IPC technique
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is now used predominantly in the experimental setting. In
RIPC, the ischemic stimulus is applied in an organ remote
to the target organ. For example, transient ischemia in the
lower limb, prior to coronary artery occlusion, reduced
infarct size in a rabbit model [4]. Neuronal and humoral
components are involved in the signal transfer from the
peripheral stimulus site to the target organ, serving as protec-
tive mediators [5]. These mediators can also be triggered by
anesthetics in the absence of preconditioning ischemic
periods [6]. Several conditions might account for the miti-
gated preconditioning effect in clinical studies. A number of
factors have been shown to mitigate preconditioning, includ-
ing advanced age and being of female sex, as well as hypergly-
cemia and β-adrenergic antagonists [7–10]. Moreover, it is
suggested that atherosclerosis with concomitant endothelial
dysfunction inhibits preconditioning. This study’s authors
have demonstrated previously that anesthetic-induced pre-
conditioning is absent in eNOS knockout mice with endo-
thelial dysfunction [11]. Reports of preconditioning in
atherosclerotic animals are inconsistent. In rabbits and rats,
hyperlipidemia and arteriosclerosis have been shown to abol-
ish preconditioning [12, 13]. However, other studies report
successful IPC or RIPC in hyperlipidemic and atherosclerotic
animals [14]. In isolated hearts of atherosclerotic mice, pre-
conditioning has been reported to be effective [15]. Whether
atherosclerosis abolishes preconditioning in vivo in mice has
not been investigated. Therefore, we induced atherosclerosis
through a high-fat diet in LDLR-/- mice and subjected these
animals in vivo to myocardial infarction with or without
anesthetic-induced and remote ischemic preconditioning.
2. Material and Methods
2.1. Animals. All experimental procedures and protocols
used in this study were reviewed and approved by the gov-
ernment of Lower Franconia’s (Bavaria, Germany) animal
care and use committee (54-2532.1-18/14). All experi-
ments conformed to the American Physiological Society’s
guiding principles in the care and use of animals and were
in accordance with the guide for the care and use of lab-
oratory animals [16].
Eight-week-old male C57BL/6 (WT) mice and LDLR-/-
(background C57BL/6) (LDLR-/-) mice were used for all
experiments (Charles River Laboratories, Sulzfeld, Germany).
The animals were housed under controlled conditions (22°C,
55-65% humidity, 12h light-dark cycle) and were allowed free
access to tap water. After a one-week acclimatization, LDLR-/-
mice were fed a high-fat diet (SM M-Z, atherogenic, +1%
cholesterol, Basis V1124) (ssniff Spezialdiäten GmbH, Soest,
Germany) for 14–16 weeks. Wild-type mice were fed a stan-
dard diet. All mice were subjected to experiments between
22 and 26 weeks of age.
2.2. Surgical Procedure. Pentobarbital sodium was used for
anesthesia induction (60mg/kg body weight i.p.) andmainte-
nance (10mg/kg/h i.p.). The mice were placed on a
temperature-controlled heated table (RT, Effenberg, Munich,
Germany) with a rectal thermometer probe attached to a
thermal feedback controller to maintain body temperature
at 36.5°C–37.5°C. After anesthesia induction, the mice were
secured in a supine position with the upper and lower
extremities attached to the table with a removable tape. The
trachea was surgically exposed, and a blunt polyethylene can-
nula (Insyte 22 g, Beckton Dickinson) was inserted into the
trachea via tracheotomy. All mice were mechanically venti-
lated with a 50 : 50 air/oxygen mixture using a rodent ventila-
tor (SAR 830/AP, CWE Inc., Ardmore, PA, USA). A 3-lead
needle-probe electrocardiogram (ECG) was attached to the
right common carotid artery, and a saline filled PE-10 cathe-
ter was inserted into the right jugular vein. The hemody-
namic parameters, namely, heart rate (HR), mean arterial
pressure (MAP), and temperature, were measured at the
end of the memory phase (MEM15′), at the end of the coro-
nary artery occlusion (CAO), and 60 minutes after reperfu-
sion (REP60′).
The mice were randomly assigned to 6 groups (N = 8 per
group). Control group mice received no further treatment in
the time-matched period prior to CAO. APC group mice
were preconditioned with 1.0 MAC sevoflurane (Sevorane®,
Abbott, Wiesbaden, Germany; 3.4 Vol-%) prior to CAO
[17]. Sevoflurane was administered for 15 minutes via a res-
pirator 30 minutes prior to CAO [18]. RIPC group mice were
subjected to a 15-minute occlusion of the left lower limb
arteria before coronary artery occlusion using a tourniquet.
All protocols were performed in bothWT and LDLR-/- mice.
Anesthetic-induced and remote ischemic preconditionings
were followed by a memory phase of 15 minutes prior to
COA. This experimental protocol is illustrated in Figure 1.
In all groups, coronary artery occlusion was performed
under an upright dissecting microscope (Zeiss Olympus
SZX12, Jena, Germany). After a left anterior thoracotomy,
exposure of the heart, and dissection of the pericardium,
the left coronary artery (LCA) was visually identified. The
LCA was ligated at the site of its emergence from under the
left atrium, resulting in a large myocardial infarction involv-
ing the anterolateral, posterior, and apical regions of the
heart [18]. Once visually identified, an 8-0 nylon suture
(Prolene, Ethicon, Norderstedt, Germany) was placed
around the LCA. CAO was performed using a hanging-
weight system [19]: in short, the LCA suture was threaded
through a small piece of blunt-edged plastic tube (PE-10 tub-
ing), and two small weights (1 g) were attached to each end.
When the weights hung freely, the LCA was immediately
occluded. LCA occlusion terminated once the weights were
supported. Successful LCA occlusion was confirmed by an
immediate change in the color of the vessel (from light red
to dark violet), the change in color of the myocardium sup-
plied by the vessel (from bright red to white), and the pres-
ence of ST elevations in the ECG. During reperfusion, the
changes in color instantly disappeared when the hanging
weights were supported and the LCA was reperfused. During
the entire procedure, the heart was kept wet with a humid
piece of absorbent cotton.
2.3. Measurement of Area at Risk andMyocardial Infarct Size.
Myocardial infarct size (IS) and area at risk (AAR) were
determined as described by Redel et al. [18]: after reperfu-
sion, the LAD was reoccluded and 1mL Evans Blue
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(0.1 g/mL; Sigma-Aldrich, Taufkirchen, Germany) and was
slowly injected into the carotid artery to delineate the
AAR. After a lethal dose injection of pentobarbital
(150μg/g i.p.), the heart was rapidly removed. The left
ventricle was dissected and cut into 8 transverse slices
1mm thick using an acrylic heart matrix (Aster Indus-
tries, McCandles, PA, USA). All slices were incubated
with 2% triphenyltetrazolium chloride (TTC, Sigma-
Aldrich, Taufkirchen, Germany), fixed overnight in 10%
formalin, weighed, and digitally photographed (Finepix
S3 Pro, Fujifilm, Tokyo, Japan). These photographs were
then analyzed with picture analysis software (Adobe Photo-
shop CS 8.0.1; Adobe Systems Inc., San Jose, CA, USA) and
the infarcted area (IA), AAR, and normal zone (NZ) were
quantified by an investigator blinded to the treatment proto-
col. The resulting fractions of IA, AAR, and NZ of each slice
were multiplied by the weight of the slice. Infarct size was
calculated by the following formula: infarct size = weight
of infarcted area/weight of area at risk × 100 ðIS = IA/AAR ×
100Þ. Mice with an AAR of less than 20% of the left ven-
tricle were excluded from further analysis.
2.4. Histological Analysis of the Aortic Root. To verify ath-
erosclerosis in high-fat/atherogenic fed LDLR-/- mice,
hematoxylin-eosin- (HE-) stained sections of the aorta
were qualitatively examined and compared with those of
wild-type mice. The aortic root was isolated, embedded in
Tissue-Tek (T.O.C. compound, Sakura Fine Technical,
Tokyo, Japan), and snap frozen in liquid nitrogen. OCT-
embedded samples were cut serially into cross-sections
(5μm thick), and hematoxylin-eosin staining was carried
out according to the manufacturer’s instructions. Using a
microscope (Leica, Wetzlar, Germany, 40x magnification),
typical arteriosclerotic morphology (foam cells, intima thick-
ness, and fibrotic cap) was quantitatively analyzed.
2.5. Vessel Contraction Myography. After euthanizing the
mouse, the vascular system was perfused and the mesenteric
vascular system was dissected. Two branches of the superior
mesenteric artery were removed for experimental purposes.
These vessel segments were clamped to a myograph between
two capillaries (111P, DMT, Aarhus, Denmark) and perfused
with oxygenated Krebs Ringer solution (37°C; pH = 7:4). The
lumen and the wall thickness of the vessel were measured
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CAO45´MEM15´ REP60´ REP120´ REP180´Sevo15´APC (WT)
CAO45´MEM15´ REP60́ REP120´ REP180´CON LDLR-/- 
RIPC LDLR-/- 
APC LDLR-/- 
CAO45´MEM15´ REP60́ REP120´ REP180´RIPC15´
CAO45´MEM15´ REP60́ REP120´ REP180´Sevo15´
Figure 1: Study protocol and time line. CONWT: control group (C57/BL6 wild type) no preconditioning; MEM15′: memory phase over 15
minutes; CAO45′: coronary artery occlusion over 45 minutes; REP60′, 120′, and 180′: reperfusion phase 60, 120, and 180 minutes after
COA45′; RIPC WT: remote ischemic preconditioning group (C57/BL6 WT); APC WT: anesthetic-induced preconditioning group
(C57/BL6 wild type); CON LDLR-/-: control group (C57/BL6 LDL-receptor deficiency); RIPC LDLR-/-: remote ischemic preconditioning
group (C57/BL6 LDL-receptor deficiency); APC LDLR-/-: anesthetic induce preconditioning group (C57/BL6 LDL-receptor deficiency). At
the end of REP180′, the mouse was sacrificed and the heart was isolated.
100 μm 100 μm 
Figure 2: Atherosclerotic vs. normal aortic root. Cross-section and
HE staining of mouse aortic root (40-fold magnification). (a) Aortic
root of a C57/BL 6 LDLR-/- mouse after 14 weeks of high-
fat/atherogenic diet. (b) Aortic root of a C57/BL 6 WT mouse
without a high-fat diet. (a) Typical criteria for severe arteriosclerosis
can be seen. Significant increase of the aortic wall thickness (black
line) compared to the WT aorta in (b). Also further typical
atherosclerotic morphological changes can be identified: plaque cap
(black arrow), foam cells, and cholesterol crystals (white arrow).
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with a calibrated video system at three different locations.
After an equilibration time, the concentrations of noradrena-
line (NA) or acetylcholine (Ach) were raised from 10-9mol/L
to 10-4mol/L. Each step introducing a new concentration
was separated by a 40-minute wash-out phase with Krebs
solution. Next, an irreversible NO synthase inhibitor L-
NAME (20-minute incubation time) was administered at a
concentration of 10-5mol/L. After a precontraction with
10-5mol/L noradrenaline, acetylcholine was administered
in increasing concentrations (10-10 to 10-4mol/L), and at
each concentration, the dilatation of the vessel lumen was
measured.
2.6. Statistics. Data are presented as mean ± SEM and were
statistically analyzed using the Mann–Whitney test and
Kruskal-Wallis test. IBM SPSS Statistics 25 software (SPSS
Inc., Armonk, NY, USA) was used for statistical analysis.
p values of <0.05 were considered statistically significant.
3. Results
Of the 67 mice assigned to the experimental protocols, 19
were excluded from the study due to asystole before the
examination ended or because of technical problems.
Twenty-four additional mice were used for histologic HE-
staining of the arteria and a myographic vessel contraction
test. A total of 91 mice were used in this investigation.
3.1. HE Staining of the Aortic Root. HE staining revealed that
in wild-type mice fed a normal diet, the vascular wall was
obviously stratified, the intima was smooth and not thick-
ened, there was no lipid deposition under the endothelial
cells, and smooth muscle cells in the media were arranged
in an orderly manner. In LDLR-/- mice fed a high-fat diet
for 12 weeks, there was significant plaque buildup under
the intima. The plaque contained foam cells and deposits of
cholesterol crystals, the intima was significantly thickened,
and the smooth muscle cells in the tunica media were disor-
dered. (Figure 2). This arteriosclerotic metamorphosis was
present in all LDLR-/- mice but in none of the wild-type
mice.
3.2. Body Weight, Temperature, and Hemodynamic
Parameters. There was no significant difference in the body
temperature of the mice. The body weight of the high-fat
diet-fed LDLR-/- mice in the control group was significantly
higher compared to that of WT mice (31:0 ± 1:1 g vs. 25:0
± 0:6 g, p = 0:01). In both the APC and RICP groups, the
LDLR-/- mice fed an atherogenic diet also had a significantly
higher body weight (Table 1).
The heart rate was significantly higher, and the MAP was
significantly lower inWTmice compared to LDLR-/- mice in
both the control and APC groups during the entire experi-
mental protocol (Table 2).
In the RIPC group, only the MEM15′ MAP was signifi-
cantly lower in WT mice compared to LDLR-/- mice
(55 ± 4mmHg vs. 63 ± 7mmHg, p = 0:002). There was no
significant difference in the other hemodynamic parameters
of this group (Table 2).
3.3. Area at Risk (AAR) and Infarct Size (IS). There was no
significant difference in the area at risk in the intragroup
comparison tests of the WT and LDLR-/- groups
(Figure 3). The LDLR-/- groups tended to have a larger
AAR than the WT mice, though in paired comparisons of
the CON, APC, and RIPC groups, only CON LDLR-/- mice
had a significantly larger AAR compared to the CON WT
(41:4 ± 4:9% vs. 30:3 ± 2:6%, p = 0:03).
Infarct size was significantly reduced in LDLR-/- mice
compared to WT mice (CON LDLR-/- (30:4 ± 4:7%) vs.
CON WT (48:0 ± 2:0%), p = 0:002; APC LDL-/- (12:1 ± 1:7
%) vs. APC WT (23:6 ± 3:8%), p = 0:002; and RICP LDLR-/-
Table 1: The body weight of LDLR-/- mice fed a atherogenic diet was significantly higher compared to that of the WT mice.
CON APC RIPC
WT 25:0 g ± 0:4 g
31:0 g ± 1:1 g
)
∗
24:5 g ± 0:6 g
30:1 g ± 0:6 g
)
∗
25:1 g ± 0:3 g









































































350 ± 5 45 ± 3 342 ± 8 49 ± 4
RIPC LDLR-/- 367 ± 6 358 ± 8 49 ± 7 350 ± 13 52 ± 8
∗p < 0:05.
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(7:5 ± 2:7%) vs. RIPC WT (23:1 ± 6:0%), p < 0:03) (Figure 4).
In wild-type mice, anesthetic-induced preconditioning (23:6 ±
3:8%; p < 0:001 vs. WT CON) and remote ischemic precondi-
tioning (23:1 ± 6:0%; p < 0:001 vs. WT CON) significantly
reduced infarct size compared to the control group (30:4 ±
4:7%). In LDLR-/- mice, anesthetic-induced preconditioning
(12:1 ± 1:7%; p = 0:005 vs. LDLR-/- CON) and remote ische-
mic preconditioning (7:5 ± 2:7%; p < 0:001 vs. LDLR-/-
CON) significantly reduced infarct size compared to the
control LDLR-/- mice (Figure 4).
3.4. Vessel Contraction Myography. The relaxation capacity
of the AMS was significantly reduced in LDLR-/- mice com-
pared to WT mice (72:9 ± 0:9% vs. 89:1 ± 0:7%; p = 0:002).
The irreversible eNOS inhibitor L-NAME reduced the relax-
ation capacity of the AMS in LDLR-/- mice from 72:9 ± 0:9%
to 60:2 ± 2:7% (p = 0:002) and in WT mice from 89:1 ± 0:7%
to 74:7 ± 1:5% (p = 0:002).
4. Discussion
The primary therapy of myocardial infarction (MI) is the
immediate revascularization of the occluded vessel. However,
the sudden reperfusion of a vessel is not without risk to the
ischemic tissue. After primary tissue damage from ischemia,
the subsequent reperfusion results in further tissue damage
[20]. This effect is known as ischemic reperfusion injury
(IRI). Data suggest that free radicals and inflammatory reac-
tion may cause this IRI effect [21, 22]. Preconditioning
through repeat sublethal ischemic periods or by pharmaco-
logical agents can render cells more resistant to IRI [1].
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Figure 3: Area at risk in % of the left ventricular area ofWT and LDLR-/- mice. Although there is a tendency that LDLR-/- mice have a higher






















































Figure 4: Infarct size: relative IS (IS/AAR) in CON, APC, and RIPC with and without LDLR-/- and high fat diet.
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decades to elucidate the underlying mechanisms and clini-
cal applicability of preconditioning [23]; this treatment
induces transcriptional and translational cellular modifica-
tions [6, 24]. In experimental studies, the effect of myocar-
dial preconditioning is tremendous. Disappointingly, in
clinical studies, the effect of myocardial preconditioning is
less prevalent or even absent [2].
Comorbidities and age may, at least in part, explain these
limited benefits of preconditioning in clinical studies. Pre-
conditioning effects have been shown to be mitigated in the
presence of different comorbidities such as artherosclerosis
[10, 25]. Arteriosclerosis can impair the endothelial NOS
function, and in eNOS-deficient mice, preconditioning is
absent [11, 26]. However, reports of preconditioning in ath-
erosclerotic animals are inconsistent [12, 15]. The aim of this
study was to use an in vivo murine atherosclerosis model to
investigate if remote and anesthetic-induced preconditioning
is impaired in these animals. Surprisingly, in our experi-
ments, preconditioning was preserved in LDL receptor-
deficient mice with dietary-induced arteriosclerosis.
In our study, we used an established animal model of ath-
erosclerosis and fed LDLR-deficient mice a high-fat diet [27].
The development of atherosclerosis was verified by histolog-
ical examinations of aortic cross sections that confirmed arte-
riosclerotic alterations of the aortic intima-media of the mice.
Whereas arteriosclerosis affects all blood vessels as a systemic
disease [28, 29], atherosclerosis does not progress linearly
and the manifestation pattern of the vessels is inhomoge-
neous. The development of arteriosclerosis is a complex pro-
cess, especially in the initial phase. Histological changes in
the aorta can be detected early, while changes in the small
vessels might occur later [30, 31]. Since we did not perform
a histological examination of the coronary arteries, we cannot
exclude that atherosclerosis and endothelial dysfunction of
the coronary arteries were in their very early stages in our
experiments. Interestingly, another study conducted on iso-
lated mouse hearts with severe atherosclerosis still reported
preserved preconditioning [15]. Ischemic preconditioning is
probably mediated in a paracrine manner, whereas remote
preconditioning can only be mediated by systemic messen-
gers. As the exact mechanisms are still not fully elucidated,
it remains unclear if the stage of atherosclerosis in the coro-
nary arteries of mice is of any relevance for the preserved pre-
conditioning effects we report.
In addition to morphological investigations, we con-
ducted experiments to examine the functional amount of
atherosclerosis and tested the relaxation of small vessels
(SMA sections) using a myograph. Even if there was some
residual eNOS-mediated vessel relaxation in atherosclerotic
LDLR-/- mice, the responsiveness of the LDLR-/- mouse
vessels to relaxation decreased overall. These data provide
evidence that atherosclerosis with endothelial dysfunction
developed on a systemic level in our experimental model.
However, since preconditioning is mediated at least in part
by endothelial NO synthase [11], we had expected our
model to show at least a reduction in infarct size through
preconditioning even with residual eNOS activity. The
completely preserved preconditioning effect cannot be
conclusively explained by our findings. It is clear that
robust cardioprotective effects independent of precondi-
tioning were activated in the mice used in our experi-
ments, since the myocardial infarct size was reduced in
the high-fat fed LDLR-/- mice compared to WT mice
under control conditions. The assumption that a high-fat
diet as such in LDLR-/- mice leads to cardioprotection is
supported by data from Girod et al., who reported that a
longer hypercholesterolemic diet in LDLR-/- mice resulted
in a reduction in IRI damage [32].
Surprisingly, preconditioning was not only preserved in
atherosclerotic LDLR-/- mice, but it indeed added to the oth-
erwise induced cardioprotection. A possible explanation
could be the interaction of eNOS and glutathione. In their
study, Girod et al. were able to demonstrate an increased glu-
tathione content in the myocardium in LDLR-/- mice with a
hypercholesterolemic diet [32]. Glutathione is a radical
scavenger and thus plays an important role in ischemia
reperfusion injury. If increased glutathione levels due to
long-term hypercholesterolemia indeed mediate cardiopro-
tective effects, this interaction with preconditioning has to
be investigated in future studies.
5. Conclusion
Taken together, long-term high-fat atherogenic diet and pre-
conditioning (APC/RIPC) seem to be an additive cardiopro-
tection in LDLR-/- mice. A cross-species statement about
factors influencing precondition ability does not seem to be
possible.
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